DAIC

JANUARY 8, 2025

a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases, hasannounced that the U.S. tim.hodson Wed, 01/08/2025 - 14:11 Jan. 8, 2025 Mineralys Therapeutics, Inc.,

Blood Pressure 52

Blood Pressure Hypertension Kidney Disease BMI 52

Cardiometabolic Health Congress

JULY 25, 2024

Practical, Future-Focused Education Cardiorenal and metabolic diseases, fueled by poor lifestyle choices and health conditions, lead to type 2 diabetes, cardiovascular disease, and chronic kidney disease. Michos, MD, MHS, FACC, FAHA, FASE, FASPC ; famed hypertension expert Keith C.

Education 100

Education Innovation Risk Factors Obesity 100

Cardiometabolic Health Congress

NOVEMBER 16, 2023

Key findings presented at the conference included disparities in access to kidney transplantation and waitlisting based on race and neighborhood characteristics, racial and ethnic differences in incident chronic kidney disease (CKD), and the use of motivational strategies to improve dialysis nonadherence among African American patients.

Kidney Disease 52

Kidney Disease Blood Pressure Diabetes Hospital 52

DAIC

JANUARY 19, 2024

milla1cf Fri, 01/19/2024 - 10:55 January 19, 2024 — Orchestra BioMed , a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the first patient was randomized in the BACKBEAT pivotal study in late December 2023. Orchestra BioMed and Medtronic, Inc. Kowal, M.D.,

Pacemaker 105

Pacemaker Hypertension Blood Pressure Kidney Disease 105

DAIC

SEPTEMBER 11, 2024

A-Fib, as the condition is commonly known, has been on the rise for at least the past decade, driven by the aging of the population, along with increasing rates of hypertension, diabetes and obesity. Digital technologies may reveal it is even more common than the current analysis indicates. million U.S. million U.S.

Atrial Fibrillation 92

Atrial Fibrillation Quality of Life Myocardial Infarction Kidney Disease 92

Cardiometabolic Health Congress

JULY 17, 2024

Aprocitentan (Tryvio) Approved: March 20, 2024 Indication: Hypertension in adults Administration: Oral Mechanism: Endothelin A and B receptor antagonist Developer: Idorsia Pharmaceuticals Significance: First and only FDA-approved endothelin receptor antagonist for high blood pressure that remains uncontrolled with existing treatments.

Tricuspid 59

Tricuspid Open-Heart Surgery Kidney Disease Pediatrics 59

Cardiometabolic Health Congress

AUGUST 8, 2024

Key contributions: Advanced cardiac imaging (e.g., high-sensitivity troponin, NT-proBNP) in risk stratification Utilization of advanced echocardiographic techniques (e.g.,

Education 59

Education Cardiovascular Disease Diabetes Kidney Disease 59